Clinical Trials Directory

Trials / Sponsors / Human Genome Sciences Inc., a GSK Company

Human Genome Sciences Inc., a GSK Company

Industry · 13 registered clinical trials.

StatusTrialPhaseStarted
CompletedBelimumab in Remission of VASculitis
Vasculitis
Phase 32013-03-20
CompletedEfficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus
Phase 42013-02-19
CompletedEfficacy and Safety of Belimumab in Patients With Active Lupus Nephritis
Lupus Nephritis
Phase 32012-07-12
SuspendedA Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
Cancer
Phase 12012-06-01
CompletedA Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Phase 42012-05-31
CompletedA Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus
Phase 32011-11-16
CompletedA Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies
Lupus Erythematosus, Discoid
—2011-05-01
CompletedStudy of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Phase 1 / Phase 22011-02-08
No Longer AvailableExpanded Access Trial of Belimumab Antibody in RA Patients Who Were Previously Treated Under HGS Protocol LBRA
Rheumatoid Arthritis
—2009-04-01
CompletedA Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
Systemic Lupus Erythematosus
Phase 32008-08-01
CompletedA Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
Phase 12008-06-01
CompletedA Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057
Systemic Lupus Erythematosus
Phase 32008-05-30
CompletedA Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02
Systemic Lupus Erythematosus
Phase 22005-05-04